GT101 not checked

Grit Biotechnology

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Recurrent or Metastatic Cervical Cancer, Solid Tumors, Adult
Main trialPhase 2
“This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.”In the company’s words, NCT06241781 on ClinicalTrials.gov

Other drugs for Recurrent or Metastatic Cervical Cancer

All 266 drugs for Recurrent or Metastatic Cervical Cancer

Coming up1

Changes1

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Jan 2027 Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer
Phase 1Active, not recruiting 25 Sep 2025 GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow GT101

Following is part of Solo: you see every change to GT101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in